WVP
CDTX

Worth Venture Partners’s Cidara Therapeutics CDTX Stock Holding History

Worth Venture Partners’s Portfolio CDTX Stock Details CDTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-6,124
Closed -$349K – 103
2020
Q3 		$349K Buy
+6,124
New +$433K 0.29% 73

Other funds holding CDTX

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
5VM
5AM Venture Management San Francisco, California $288M AUM 313.93% 1-Year Est. Return
OFM
Omega Fund Management Boston, Massachusetts $186M AUM 155.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
IVM
InterWest Venture Management San Francisco, California $20.6M AUM 48.5% 1-Year Est. Return
ACM
Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Worth Venture Partners's CDTX Position: Q4 2020 in Review

Worth Venture Partners sold out of Cidara Therapeutics (CDTX) in Q4 2020, closing a stake of 6,124 shares — an estimated $349K sold.

Worth Venture Partners first reported a position in CDTX in Q3 2020 and held it in 1 quarter. The position peaked at $349K in Q3 2020. 63 funds tracked by Wall St. Rank hold CDTX as of Q4 2020.

  • Worth Venture Partners reported no remaining Cidara Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Worth Venture Partners sold 6,124 Cidara Therapeutics shares in Q4 2020, an estimated $349K.
  • Worth Venture Partners first reported a position in Cidara Therapeutics in Q3 2020 and held it in 1 quarter.
  • Worth Venture Partners's Cidara Therapeutics position peaked at $349K in Q3 2020.
  • 63 funds tracked by Wall St. Rank held Cidara Therapeutics as of Q4 2020.

Based on Worth Venture Partners's 13F filing for Q4 2020, filed 17 Feb 2021.